Representative Investments
News Provided By our Investments
- Intrexon to Acquire 48% Stake in AquaBounty Technologies
- ZIOPHARM Oncology Announces Compelling Clinical Activity in Phase 1 Study of Ad-RTS IL-12 in Advanced Melanoma and Dosing of First Patient in Phase 2 Study
- Fibrocell Science, Inc. Announces $45 Million Private Placement and Enters Strategic Collaboration with Intrexon
- Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections

